Miguel Angel Climent Duran

机构：Fundación Instituto Valenciano de Oncología · ORCID：0000-0001-7523-0212

发表论文 105 篇 · 总被引 1211 次 · h-index 13

代表论文

• Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (2022 · The Lancet Oncology · 被引 296)
• Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study (2024 · Journal of Clinical Oncology · 被引 177)
• Real-world prostate-specific antigen reduction and survival outcomes of metastatic hormone-sensitive prostate cancer patients treated with apalutamide: An observational, retrospective, and multicentre study (2023 · Prostate International · 被引 25)
• Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance (2023 · European Urology · 被引 25)
• SEOM-GG clinical guidelines for the management of germ-cell testicular cancer (2023) (2024 · Clinical & Translational Oncology · 被引 18)
• Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patients (2025 · ESMO Open · 被引 13)